AnaptysBio, Inc.
Antibodies Directed Against Programmed Death-1 (PD-1)

Last updated:

Abstract:

The disclosure provides antibody agents that bind to a programmed death-1 (PD-1) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided are related nucleic acids, vectors, compositions, and methods of using the anti-PD-1 antibody agent to treat a disorder or disease that is responsive to PD-1 inhibition, such as cancer or an infectious disease.

Status:
Application
Type:

Utility

Filling date:

27 Sep 2021

Issue date:

24 Mar 2022